Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$66.81 - $80.83 $3.01 Million - $3.64 Million
45,000 Added 28.13%
205,000 $16 Million
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $9.76 Million - $11.1 Million
160,000 New
160,000 $10.8 Million
Q4 2022

Feb 14, 2023

BUY
$54.21 - $70.44 $34.5 Million - $44.9 Million
636,800 Added 113.07%
1,200,000 $81.4 Million
Q3 2022

Nov 14, 2022

SELL
$53.02 - $135.75 $156 Million - $399 Million
-2,935,800 Reduced 83.9%
563,200 $30.9 Million
Q2 2022

Aug 15, 2022

SELL
$59.26 - $71.14 $11.9 Million - $14.3 Million
-201,000 Reduced 5.43%
3,499,000 $231 Million
Q1 2022

May 16, 2022

BUY
$55.72 - $67.12 $46.4 Million - $55.9 Million
832,800 Added 29.05%
3,700,000 $245 Million
Q4 2021

Feb 14, 2022

BUY
$54.02 - $63.83 $78.6 Million - $92.9 Million
1,455,200 Added 103.06%
2,867,200 $167 Million
Q3 2021

Nov 15, 2021

BUY
$55.56 - $60.79 $78.5 Million - $85.8 Million
1,412,000 New
1,412,000 $84.8 Million
Q2 2021

Aug 16, 2021

SELL
$48.42 - $60.18 $177 Million - $220 Million
-3,650,500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$47.16 - $54.44 $63.7 Million - $73.5 Million
1,350,500 Added 58.72%
3,650,500 $182 Million
Q4 2020

Feb 16, 2021

BUY
$48.52 - $58.02 $112 Million - $133 Million
2,300,000 New
2,300,000 $115 Million
Q3 2020

Nov 16, 2020

SELL
$53.07 - $61.1 $17.3 Million - $19.9 Million
-325,990 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$43.1 - $55.31 $14.1 Million - $18 Million
325,990 New
325,990 $17.2 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.